Endeavor BioMedicines Receives Orphan Drug Designation for Taladegib

Strategic Insights -

Endeavor BioMedicines announced that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to its investigational therapy, taladegib (ENV-101), for the treatment of idiopathic pulmonary fibrosis (IPF). This designation provides special incentives, including eligibility for protocol assistance, exemptions or reductions in regulatory fees, and 10 years of marketing exclusivity in the EU. The FDA grants Orphan Drug Designation to drugs affecting fewer than 200,000 people in the U.S., offering financial incentives and up to seven years of market exclusivity.

Key Takeaways:

  • The FDA and EC have granted Orphan Drug Designation to taladegib (ENV-101) for the treatment of idiopathic pulmonary fibrosis (IPF), making it eligible for protocol assistance and 10 years of marketing exclusivity in the EU.
  • The designation also includes eligibility for exemptions or reductions in certain regulatory fees and provides financial incentives to support clinical development.
  • Taladegib is a Hedgehog (Hh) signaling pathway inhibitor, which may resolve the excessive wound-healing process seen in IPF by stopping the abnormal accumulation of myofibroblasts that cause fibrosis.
  • Endeavor BioMedicines is currently enrolling patients in the Phase 2b WHISTLE-PF trial of taladegib in IPF, a chronic, progressive lung disease with limited treatment options.
  • The WHISTLE-PF trial will evaluate the efficacy of a range of taladegib doses, characterize the investigational compound's safety and tolerability, and assess its effect on patient reported outcomes and lung function.
  • IPF is a chronic, progressive lung disease that affects more than 150,000 adults in the United States, while the average life expectancy after diagnosis is three to five years.
  • Lisa Lancaster, M.D., Chief Medical Officer, Endeavor BioMedicines, stated that the Orphan Drug Designation underscores the significant unmet medical need for patients with IPF.

Statistics:

  • More than 150,000 adults in the United States are affected by IPF.
  • The average life expectancy after diagnosis is three to five years.
  • Taladegib (ENV-101) is eligible for up to seven years of market exclusivity in the U.S.
  • The Phase 2b WHISTLE-PF trial is expected to be completed in 2026.

Sources:

  • Endeavor BioMedicines
  • [FDA Grants Orphan Designation to Drugs for Rare Diseases, (FDASIA)]
  • [EC Committee for Orphan Medicinal Products, (EC)]